Inflammatory Bowel Diseases最新文献

{"title":"Large-scale proteomics identifies a pretreatment Crohn's disease core proteome and a dynamic signature for anti-TNF response.","authors":"Rebekah Karns, Jeffrey S Hyams, Brendan M Boyle, Joshua D Noe, Kimberly Jackson, Kimberly Lynch, Mary Kate Ewalt, Alex Nasr, Thomas Aviles, Lee A Denson, Phillip Minar","doi":"10.1093/ibd/izag221","DOIUrl":"https://doi.org/10.1093/ibd/izag221","url":null,"abstract":"<p><strong>Background: </strong>With modest rates of endoscopic remission to anti-TNF biologics in children with moderate-to-severe Crohn's disease (CD), there is a critical need to develop noninvasive biomarkers associated with anti-TNF response. We performed a comprehensive proteomic evaluation to identify peripheral-blood candidate biomarkers for anti-TNF response.</p><p><strong>Methods: </strong>The ENvISION study enrolled patients (2-19 years old) with CD prior to starting infliximab or adalimumab with outcomes prospectively monitored at Month 3 (M3) and Month 12 (M12). The SomaScan® (Somalogic, Boulder, CO, 7322 analytes) was performed prior to anti-TNF treatment (baseline) at M3 and M12. Endoscopic remission was assessed at M12 (simple endoscopic score-CD < 3).</p><p><strong>Results: </strong>Eighty patients with CD were enrolled with the CD Core Proteome developed from 61 prednisone-naive CD and 30 healthy controls. We identified 2999 differentially abundant proteins, 1403 with lower abundance and 1596 with higher abundance (FDR < 0.05). The CD Core Proteome was then compared across the three timepoints (baseline, M3 and M12) and we found that at both M3 and M12, the Core Proteome dysregulation retains strong identity with the baseline protein signal (β = .7, P < .001; β = .63, P < .001, respectively). Although the proteome exhibits change over time, it does not revert to a control-like state; rather, it transitions to a distinct \"treated CD\" proteome. In an exploratory investigation of the change in (delta) protein abundance from baseline to M3, we identified 132 proteins nominally associated with M12 endoscopic remission (P < .01). Using elastic net regression, we identified a three-protein panel (IRF1, NEUROG1, and APOA5) associated with M12 endoscopic remission (AUROC 0.94, 95% CI 0.88-1.0).</p><p><strong>Conclusions: </strong>In an exploratory investigation, we identified a CD Core Proteome and three-protein panel whose early changes were associated with M12 endoscopic remission, supporting their use as early pharmacodynamic response markers following external validation.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149227680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GLP-1 receptor agonists and symptomatic remission in ulcerative colitis: A credible signal that welcomes prospective study.","authors":"Budoor Alqinai, Swapna Gayam, Jennifer Hadam-Veverka","doi":"10.1093/ibd/izag216","DOIUrl":"https://doi.org/10.1093/ibd/izag216","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149206827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GLP-1 receptor agonists and symptomatic remission in ulcerative colitis: how large an effect is credible?","authors":"Besim Fazil Agargun, Burce Isik, Ali Emre Bardak, Bilger Cavus, Filiz Akyuz","doi":"10.1093/ibd/izag215","DOIUrl":"https://doi.org/10.1093/ibd/izag215","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149193267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lower rates of endoscopic remission among incarcerated patients with inflammatory bowel disease.","authors":"Trevor Schell, Joshua Kalapala, Bruin Armwald, Andrew Turunen, Monica Zablotney, Farah A Kaiksow, Mark Benson, Megan K Lutz","doi":"10.1093/ibd/izag211","DOIUrl":"https://doi.org/10.1093/ibd/izag211","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149181632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health-related quality of life after diagnosis of ulcerative colitis and Crohn's disease: 3-year trajectories and factors associated with clinically meaningful improvement (the IBSEN III cohort).","authors":"Bjorn Christian Olsen, Milada Hagen, Randi Opheim, Vendel A Kristensen, Charlotte Lund, Tone B Aabrekk, Ingunn Johansen, Kristina I Aass Holten, Vibeke Strande, Ida Frivold Glad, May-Bente Bengtson, Trond Espen Detlie, Asle W Medhus, Raziye Boyar, Roald Torp, Simen Vatn, Svein Oskar Frigstad, Tomm Bernklev, Lars-Petter Jelsness-Jørgensen, Marte Lie Høivik, Gert Huppertz-Hauss","doi":"10.1093/ibd/izag196","DOIUrl":"https://doi.org/10.1093/ibd/izag196","url":null,"abstract":"<p><strong>Background: </strong>Evidence for the clinical importance of changes in health-related quality of life (HRQoL) over time in unselected patients with ulcerative colitis (UC) and Crohn's disease (CD) is limited. We aimed to describe HRQoL trajectories, determine clinically meaningful HRQoL improvement, and identify factors associated with such improvement during the first 3 years after diagnosis.</p><p><strong>Methods: </strong>Adults with UC and CD from a population-based inception cohort completed the Inflammatory Bowel Disease Questionnaire (IBDQ) and the 36-Item Short Form Survey (SF-36) at inclusion and at the 1-year and 3-year follow-ups. HRQoL trajectories were estimated using linear mixed-effects models. Clinically meaningful improvement was defined using established minimal clinically important difference (MCID) thresholds (IBDQ ≥16; SF-36 physical and mental component summary scores ≥3). Associations between prespecified variables and MCID achievement at follow-up were assessed using multivariable logistic regression.</p><p><strong>Results: </strong>Among 1016 patients (UC: 68%; CD: 32%), IBDQ and SF-36 physical and mental component summary scores improved at both follow-ups, and approximately half of the patients achieved the corresponding MCID thresholds. HRQoL scores remained below general Norwegian population norms, and trajectories were similar for UC and CD. Symptomatic remission was consistently associated with higher odds of clinically meaningful HRQoL improvement, whereas depressive symptoms, substantial fatigue, and irritable bowel-like symptoms were associated with lower odds. Endoscopic remission, biologic therapy, and bowel surgery during the first year were not significantly associated with clinically meaningful improvement.</p><p><strong>Conclusions: </strong>Clinically meaningful HRQoL improvement was achieved by about half of the patients and was consistently associated with lower symptom and psychosocial burden.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149181699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The right dose for the right patient: Toward precision infliximab therapy in acute severe ulcerative colitis.","authors":"Manjeet K Goyal, Shrinivas Bishu","doi":"10.1093/ibd/izag204","DOIUrl":"https://doi.org/10.1093/ibd/izag204","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149181680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Screening and management of coccidioidomycosis in patients with inflammatory bowel disease on immunosuppressive therapies.","authors":"Marina I Ivanov, Janis E Blair, Guilherme P Ramos","doi":"10.1093/ibd/izag197","DOIUrl":"https://doi.org/10.1093/ibd/izag197","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149181675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"B cells regulate T cell transfer colitis by partially reconstituting luminal IgA and modulating the colonic microbiota.","authors":"Josef Urrete, Margaret Kim, Amruth Chilukuri, Prabhdeep Kaur, Zining Shen, Mark Holton, Paul Jedlicka, Guillaume Urtecho, Giorgos Bamias, Jesús Rivera-Nieves","doi":"10.1093/ibd/izag198","DOIUrl":"https://doi.org/10.1093/ibd/izag198","url":null,"abstract":"<p><p>Loss of immune tolerance to commensal microbial antigens is a central driver of inflammatory bowel disease. While regulatory T cells are well recognized in maintaining intestinal homeostasis, the contribution of B cells-particularly IgA-secreting cells-remains incompletely defined. In the T cell transfer colitis model, cotransfer of splenic B cells attenuates disease, an effect largely attributed to IL-10-producing regulatory B cells (Bregs). However, alternative B cell-dependent mechanisms have not been fully explored. Here, we investigated whether splenic B cells regulate T cell transfer colitis through IgA-dependent mechanisms independent of Breg-associated cytokines. We show that splenic B cells from wild-type C57BL/6 (B6) mice reconstitute bone marrow and peripheral B cell compartments in RAG1⁻/⁻ recipients, undergo class switching, migrate to the colonic lamina propria as sIgA⁺ B lineage cells, and partially restore luminal secretory IgA. B cell cotransfer significantly attenuated clinical and histological colitis without increased expression of canonical Breg-associated cytokines, including interleukin-10, transforming growth factor β, and interleukin-35 subunits. In contrast, splenic B cells from IgA-deficient mice failed to attenuate colitis despite comparable peripheral B cell reconstitution. Restoration of secretory IgA was associated with increased bacterial IgA coating, reduced fecal bacterial burden, and remodeling of the colonic microbiota, including enrichment of beneficial commensal taxa. Importantly, because IgA-deficient B cells failed to attenuate colitis despite comparable peripheral B cell reconstitution, these findings support an important role for IgA in mediating the protective effect of B cell transfer. Collectively, these findings identify IgA-mediated modulation of the microbiota as an alternate mechanism by which B cells attenuate T cell transfer colitis, highlighting a Breg-independent regulatory pathway with potential relevance to inflammatory bowel disease pathogenesis.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149170469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to \"Isolated perianal Crohn's disease: the next challenge is long-term surveillance\".","authors":"Wasuwit Wanchaitanawong, Julajak Limsrivilai","doi":"10.1093/ibd/izag207","DOIUrl":"https://doi.org/10.1093/ibd/izag207","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149147336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Morganella morganii-derived histamine impairs intestinal barrier function via HRH4 and aggravates colitis.","authors":"Youcai Yi, Rui Feng, Xueting Wu, Xiaochen Zhu, Liyuan Xiang, Kangrong Zheng, Shu Xu, Wenhua Lai, Yijun Zhu, Minhu Chen","doi":"10.1093/ibd/izag201","DOIUrl":"https://doi.org/10.1093/ibd/izag201","url":null,"abstract":"<p><strong>Background: </strong>Pro-inflammatory dietary patterns are associated with an increased risk of Crohn's disease (CD) and shifts in the gut microbiota. Our previous multi-omics analysis had identified the enrichment of Morganella morganii (M. morganii) in both patients with CD and individuals consuming pro-inflammatory diets. In this study, we aimed to investigate the role and potential mechanisms by which M. morganii contributes to intestinal inflammation.</p><p><strong>Methods: </strong>Using murine models of colitis, mouse colon organoids, and epithelial cell systems, combined with metabolomic profiling and pharmacological interventions, we investigated the effects of M. morganii and its secreted metabolites on tight junction integrity and intestinal permeability.</p><p><strong>Results: </strong>M. morganii aggravated colitis severity and induced a remarkable increase in intestinal permeability with disruption of tight junction architecture, including reduced occludin and zonula occludens-1 (ZO-1) expression and ultrastructural damage. These effects were predominantly mediated by the secreted low-molecular-weight metabolites rather than by bacterial invasion. Metabolomic analysis of the <3-kDa fraction of M. morganii culture supernatant identified histamine as a key bioactive molecule. Histamine recapitulated barrier disruption and colitis exacerbation in vivo. Pharmacological studies suggested that histamine-induced injury is mediated mainly through the histamine receptor H4 (HRH4) and that the inhibition of histamine synthesis significantly restored barrier integrity and alleviated colitis.</p><p><strong>Conclusions: </strong>These findings suggest a previously unrecognized pathway in which the diet-responsive pathobiont M. morganii may impair epithelial barrier integrity through histamine-HRH4 signaling. Targeting histamine synthesis and HRH4 may offer a potential therapeutic avenue worth further investigation.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149149326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}